Standard
Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. / Hansen, Ann-Brit Eg; Obel, N; Nielsen, H; Pedersen, C; Gerstoft, J.
In:
HIV Medicine, Vol. 12, No. 3, 01.03.2011, p. 157-65.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Hansen, A-BE
, Obel, N, Nielsen, H, Pedersen, C
& Gerstoft, J 2011, '
Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial',
HIV Medicine, vol. 12, no. 3, pp. 157-65.
https://doi.org/10.1111/j.1468-1293.2010.00864.xAPA
Hansen, A-B. E.
, Obel, N., Nielsen, H., Pedersen, C.
, & Gerstoft, J. (2011).
Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
HIV Medicine,
12(3), 157-65.
https://doi.org/10.1111/j.1468-1293.2010.00864.xVancouver
Hansen A-BE
, Obel N, Nielsen H, Pedersen C
, Gerstoft J.
Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
HIV Medicine. 2011 Mar 1;12(3):157-65.
https://doi.org/10.1111/j.1468-1293.2010.00864.xAuthor
Hansen, Ann-Brit Eg ; Obel, N ; Nielsen, H ; Pedersen, C ; Gerstoft, J. / Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. In: HIV Medicine. 2011 ; Vol. 12, No. 3. pp. 157-65.
Bibtex
@article{04c0a676dd344e51b26319c4f38b2c64,
title = "Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial",
abstract = "The aim of the study was to compare changes in bone mineral density (BMD) over 144 weeks in HIV-infected patients initiating nucleoside reverse transcriptase inhibitor (NRTI)-sparing or protease inhibitor-sparing highly active antiretroviral therapy (HAART).",
author = "Hansen, {Ann-Brit Eg} and N Obel and H Nielsen and C Pedersen and J Gerstoft",
note = "{\textcopyright} 2010 British HIV Association.",
year = "2011",
month = mar,
day = "1",
doi = "http://dx.doi.org/10.1111/j.1468-1293.2010.00864.x",
language = "English",
volume = "12",
pages = "157--65",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "3",
}
RIS
TY - JOUR
T1 - Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial
AU - Hansen, Ann-Brit Eg
AU - Obel, N
AU - Nielsen, H
AU - Pedersen, C
AU - Gerstoft, J
N1 - © 2010 British HIV Association.
PY - 2011/3/1
Y1 - 2011/3/1
N2 - The aim of the study was to compare changes in bone mineral density (BMD) over 144 weeks in HIV-infected patients initiating nucleoside reverse transcriptase inhibitor (NRTI)-sparing or protease inhibitor-sparing highly active antiretroviral therapy (HAART).
AB - The aim of the study was to compare changes in bone mineral density (BMD) over 144 weeks in HIV-infected patients initiating nucleoside reverse transcriptase inhibitor (NRTI)-sparing or protease inhibitor-sparing highly active antiretroviral therapy (HAART).
U2 - http://dx.doi.org/10.1111/j.1468-1293.2010.00864.x
DO - http://dx.doi.org/10.1111/j.1468-1293.2010.00864.x
M3 - Journal article
VL - 12
SP - 157
EP - 165
JO - HIV Medicine
JF - HIV Medicine
SN - 1464-2662
IS - 3
ER -
